Search Results - "Coats, M. E."

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis by RUDICK, R. A, SIMONIAN, N. A, MASS, M. K, RICHERT, J. R, SALAZAR, A. M, MUNSCHBAUER, F. E, COOKFAIR, D. L, SIMON, J. H, JACOBS, L. D, ALAM, J. A, CAMPION, M, SCARAMUCCI, J. O, JONES, W, COATS, M. E, GOODKIN, D. E, WEINSTOCK-GUTTMAN, B, HERNDON, R. M

Get full text

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis by RUDICK, R. A, GOODKIN, D. E, ALAM, J. J, SIMONIAN, N. A, CAMPION, M. K, BARTOSZAK, D. M, BOURDETTE, D. N, BRAIMAN, J, BROWNSCHEIDLE, C. M, COATS, M. E, COHAN, S. L, DOUGHERTY, D. S, JACOBS, L. D, KINKEL, R. P, MASS, M. K, MUNSCHAUER, F. E, PRIORE, R. L, PULLICINO, P. M, SCHEROKMAN, B. J, WEISTOCK-GUTTMAN, B, WHITHAM, R. H, COOKFAIR, D. L, HERNDON, R. M, RICHERT, J. R, SALAZAR, A. M, FISCHER, J. S, GRANGER, C. V, SIMON, J. H

Get full text

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis: Multiple sclerosis by RUDICK, R. A, GOODKIN, D. E, ALAM, J. J, SIMONIAN, N. A, CAMPION, M. K, BARTOSZAK, D. M, BOURDETTE, D. N, BRAIMAN, J, BROWNSCHEIDLE, C. M, COATS, M. E, COHAN, S. L, DOUGHERTY, D. S, JACOBS, L. D, KINKEL, R. P, MASS, M. K, MUNSCHAUER, F. E, PRIORE, R. L, PULLICINO, P. M, SCHEROKMAN, B. J, WEISTOCK-GUTTMAN, B, WHITHAM, R. H, COOKFAIR, D. L, HERNDON, R. M, RICHERT, J. R, SALAZAR, A. M, FISCHER, J. S, GRANGER, C. V, SIMON, J. H

Get full text

Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals by Martin, A, Heyes, M P, Salazar, A M, Kampen, D L, Williams, J, Law, W A, Coats, M E, Markey, S P

“…Neuropsychological functioning and cerebrospinal fluid concentrations of an endogenous neurotoxin, quinolinic acid (QUIN) were evaluated in 52 HIV-positive…”
Get more information

The maximally attainable V.o2 during exercise in humans: the peak vs. maximum issue by Day, J. R, Rossiter, H. B, Coats, E. M, Skasick, A, Whipp, B. J

“…1 Department of Physiology, St. George's Hospital Medical School, London SW17 ORE, United Kingdom; 2 Division of Physiology, Department of Medicine, University…”
Get full text

Meige's disease and a positive treatment response with deanol by Coats, M E

Get more information

Embryo transfer techniques and their impact on the outcome of assisted conception by Coats, E M

“…This thesis describes the development of a novel system to grade the ‘difficulty’ of an embryo transfer (ET) procedure. A systematic review of the prevalence…”
Get full text

Embryo Transfer Techniques and Their Impact on the Outcome of Assisted Conception by Coats, E M

“…This thesis describes the development of a novel system to grade the ‘difficulty’ of an embryo transfer (ET) procedure. A systematic review of the prevalence…”
Get full text

Evaluation of the Charcoal Card Test for Trichinosis in Swine by Coats, M. E., Leland, S. E., Kelley, D. C.

Get full text

The maximally attainable VO sub(2) during exercise in humans: The peak vs. maximum issue by Day, J R, Rossiter, H B, Coats, E M, Skasick, A, Whipp, B J

“…The quantification of maximum oxygen uptake (VO sub(2max)), a parameter characterizing the effective integration of the neural, cardiopulmonary, and metabolic…”
Get full text

The maximally attainable V̇ o 2 during exercise in humans: the peak vs. maximum issue by Day, J. R., Rossiter, H. B., Coats, E. M., Skasick, A., Whipp, B. J.

“…The quantification of maximum oxygen uptake (V̇o 2 max ), a parameter characterizing the effective integration of the neural, cardiopulmonary, and metabolic…”
Get full text

Intensity-dependent tolerance to exercise after attaining VO2 max in humans by Coats, Edward M, Rossiter, Harry B, Day, James R, Miura, Akira, Fukuba, Yoshiyuki, Whipp, Brian J

“…1 Department of Physiology, St. George's Hospital Medical School, Cranmer Terrace, London, United Kingdom; 2 Department of Medicine, Division of Physiology,…”
Get full text

Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis by Herndon, Robert M, Rudick, Richard A, Munschauer, Frederick E, Mass, Michele K, Salazar, Andres M, Coats, Michael E, Labutta, Robert, Richert, John R, Cohan, Stanley L, Genain, Claude, Goodkin, Donald, Toal, Martin, Riester, Katherine

“…An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFNβ-1a-Avonex) was conducted to evaluate the immunogenicity and…”
Get full text

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997 by Rudick, R A, Goodkin, D E, Jacobs, L D, Cookfair, D L, Herndon, R M, Richert, J R, Salazar, A M, Fischer, J S, Granger, C V, Simon, J H, Alam, J J, Simonian, N A, Campion, M K, Bartoszak, D M, Bourdette, D N, Braiman, J, Brownscheidle, C M, Coats, M E, Cohan, S L, Dougherty, D S, Kinkel, R P, Mass, M K, Munschauer, F E, Priore, R L, Pullicino, P M, Scherokman, B J, Weistock-Guttman, B, Whitham, R H

Get full text

Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis by Rudick, Richard A., Cookfair, Diane L., Simonian, Nancy A., Ransohoff, Richard M., Richert, John R., Jacobs, Lawrence D., Herndon, Robert M., Salazar, Andres M., Fischer, Jill S., Granger, Carl V., Goodkin, Donald E., Simon, Jack H., Bartoszak, David M., Bourdette, Dennis N., Braiman, Jonathan, Brownscheidle, Carol M., Coats, Michael E., Cohan, Stanley L., Dougherty, David S., Kinkel, Revere P., Mass, Michele K., Munchsauer, Frederick E., O'Reilly, Kathy, Priore, Roger L., Pullicino, Patrick M., Scherokman, Barbara J., Wende, Karl, Weinstock-Guttman, Bianca, Whitham, Ruth H.

“…Background and objective: This report provides results of CSF analyses done in a subset of relapsing remitting MS patients participating in a…”
Get full text

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) by Rudick, R A, Simonian, N A, Alam, J A, Campion, M, Scaramucci, J O, Jones, W, Coats, M E, Goodkin, D E, Weinstock-Guttman, B, Herndon, R M, Mass, M K, Richert, J R, Salazar, A M, Munschauer, 3rd, F E, Cookfair, D L, Simon, J H, Jacobs, L D

“…Interferon beta is an effective treatment for relapsing multiple sclerosis (MS). As with other protein drugs, neutralizing antibodies (NAB) can develop that…”
Get full text

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group by Rudick, R A, Cookfair, D L, Simonian, N A, Ransohoff, R M, Richert, J R, Jacobs, L D, Herndon, R M, Salazar, A M, Fischer, J S, Granger, C V, Goodkin, D E, Simon, J H, Bartoszak, D M, Bourdette, D N, Braiman, J, Brownscheidle, C M, Coats, M E, Cohan, S L, Dougherty, D S, Kinkel, R P, Mass, M K, Munchsauer, F E, O'Reilly, K, Priore, R L, Whitham, R H

“…This report provides results of CSF analyses done in a subset of relapsing remitting MS patients participating in a placebo-controlled, double-blind, phase III…”
Get full text

Eight-year immunogenicity and safety of interferon beta-1a-Avonex registered treatment in patients with multiple sclerosis by Herndon, R M, Rudick, R A, Munschauer, FE III, Mass, M K, Salazar, A M, Coats, ME, Labutta, R, Richert, J R, Cohan, S L, Genain, C, Goodkin, D, Toal, M, Riester, K

“…An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFN beta -1a-Avonex) was conducted to evaluate the immunogenicity and…”
Get full text

Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG) by Goodkin, D E, Priore, R L, Wende, K E, Campion, M, Bourdette, D N, Herndon, R M, Fischer, J S, Jacobs, L D, Cookfair, D L, Rudick, R A, Richert, J R, Salazar, A M, Granger, C V, Simon, J H, Alam, J J, Bartoszak, D M, Braiman, J, Brownscheidle, C M, Coats, M E, Cohan, S L, Dougherty, D S, Kinkel, R P, Mass, M K, Munschauer, 3rd, F E, Whitham, R H

“…We compared the ability of the Kurtzke Expanded Disability Status Scale (EDSS) and a composite outcome of non-physician-based measures of time to ambulate 25…”
Get more information

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) by Rudick, R A, Goodkin, D E, Jacobs, L D, Cookfair, D L, Herndon, R M, Richert, J R, Salazar, A M, Fischer, J S, Granger, C V, Simon, J H, Alam, J J, Simonian, N A, Campion, M K, Bartoszak, D M, Bourdette, D N, Braiman, J, Brownscheidle, C M, Coats, M E, Cohan, S L, Dougherty, D S, Kinkel, R P, Mass, M K, Munschauer, F E, Priore, R L, Whitham, R H

“…A phase III double-blind, placebo-controlled clinical trial demonstrated that interferon beta-1a (IFN beta-1a) (Avonex, Biogen) significantly delayed…”
Get full text